- Home
- TGB vs IMTX Comparison
TGB vs IMTX Comparison
Compare TGB & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TGB | IMTX |
|---|---|---|
| Founded | 1966 | N/A |
| Country | Canada | Germany |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TGB | IMTX |
|---|---|---|
| Price | $5.18 | $9.95 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $5.00 | ★ $19.25 |
| AVG Volume (30 Days) | ★ 6.2M | 592.7K |
| Earning Date | 11-12-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $428,559,326.00 | $99,445,031.00 |
| Revenue This Year | $10.35 | N/A |
| Revenue Next Year | $61.39 | $24.39 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 0.50 | N/A |
| 52 Week Low | $1.67 | $3.30 |
| 52 Week High | $5.57 | $12.41 |
Technical Indicators
Market Signals| Indicator | TGB | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 57.42 | 48.43 |
| Support Level | $5.03 | $9.85 |
| Resistance Level | $5.57 | $10.31 |
| Average True Range (ATR) | 0.23 | 0.66 |
| MACD | -0.02 | -0.09 |
| Stochastic Oscillator | 29.46 | 8.65 |
Price Performance
Historical ComparisonAbout TGB Taseko Mines Ltd.
Taseko Mines Ltd is a Canadian mining company. It is principally engaged in the production and sale of metals, as well as related activities, including exploration and mine development, within the province of British Columbia, Canada, and the State of Arizona, the United States. The Gibraltar, Aley, New Prosperity, Yellowhead properties are located in British Columbia whereas Florence copper is in central Arizona.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.